Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Depreciation & Amortization (CF): 2021-2025

Historic Depreciation & Amortization (CF) for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $384,000.

  • Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) fell 3.76% to $384,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 18.96%. This contributed to the annual value of $1.7 million for FY2024, which is 27.60% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Depreciation & Amortization (CF) stood at $384,000 for Q3 2025, which was up 7.26% from $358,000 recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) peaked at $717,000 during Q2 2021, and registered a low of $312,000 during Q1 2021.
  • Its 3-year average for Depreciation & Amortization (CF) is $465,727, with a median of $430,000 in 2024.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) surged by 110.26% in 2022, and later tumbled by 33.83% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Depreciation & Amortization (CF) (Quarterly) stood at $668,000 in 2021, then decreased by 9.88% to $602,000 in 2022, then declined by 10.30% to $540,000 in 2023, then decreased by 25.93% to $400,000 in 2024, then decreased by 3.76% to $384,000 in 2025.
  • Its Depreciation & Amortization (CF) was $384,000 in Q3 2025, compared to $358,000 in Q2 2025 and $345,000 in Q1 2025.